ArticleFrontiers in immunology2026
Fraxinellone mitigates acute lung injury by targeting HIF-1α to suppress pyroptosis and inflammation.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Acute pulmonary contusion (APC), a life-threatening trauma-associated condition, currently lacks targeted pharmacological therapies. Fraxinellone (FRA) inhibits Hypoxia-inducible factor-1α (HIF-1α) synthesis, but its binding mechanism and anti-APC action remain unclear. This study was designed to assess the therapeutic potential of FRA, a natural substance with known anti-inflammatory properties, as a means of attenuating APC progression through the inhibition of HIF-1α. Methods: An Results: FRA notably diminished APC severity by reducing pulmonary edema (wet/dry ratio), lowering pro-inflammatory cytokine levels ((interleukin-1β [IL-1β], interleukin-6 [IL-6], interleukin-18 [IL-18]), and decreasing pyroptosis markers (NOD-like receptor family pyrin domain containing 3 [NLRP3], gasdermin D [GSDMD]) in both Conclusion: FRA mitigates APC progression by targeting HIF-1α to suppress NLRP3/GSDMD-mediated pyroptosis and inflammation, providing a novel therapeutic approach for trauma-induced lung injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.